Supernus Pharmaceuticals Inc. (SUPN) PT Set at $28.00 by Jefferies Group
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) has been given a $28.00 target price by equities researchers at Jefferies Group in a research note issued to investors on Thursday. The firm presently has a a “buy” rating on the specialty pharmaceutical company’s stock. Jefferies Group’s target price points to a potential upside of 29.99% from the stock’s previous close.
A number of other analysts have also commented on SUPN. Zacks Investment Research raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a report on Wednesday, July 6th. Northland Securities downgraded Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price on the stock. in a research note on Monday, July 18th. Finally, Piper Jaffray Cos. downgraded Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 target price on the stock. in a research note on Monday, July 18th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Supernus Pharmaceuticals currently has an average rating of “Buy” and an average target price of $25.25.
Supernus Pharmaceuticals (NASDAQ:SUPN) traded up 2.3979% during trading on Thursday, reaching $22.0565. The company’s stock had a trading volume of 756,277 shares. The stock’s 50 day moving average is $23.58 and its 200 day moving average is $20.23. The company has a market cap of $1.09 billion, a price-to-earnings ratio of 45.0133 and a beta of 1.73. Supernus Pharmaceuticals has a 12 month low of $9.51 and a 12 month high of $26.84.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/supernus-pharmaceuticals-inc-supn-pt-set-at-28-00-by-jefferies-group.html
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.05. The firm earned $50.40 million during the quarter, compared to analyst estimates of $49.67 million. Supernus Pharmaceuticals had a return on equity of 20.99% and a net margin of 14.94%. The company’s revenue for the quarter was up 43.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.03 EPS. On average, equities analysts expect that Supernus Pharmaceuticals will post $0.68 EPS for the current fiscal year.
In related news, CFO Gregory S. Patrick sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, September 16th. The stock was sold at an average price of $25.00, for a total value of $50,000.00. Following the transaction, the chief financial officer now owns 3,616 shares in the company, valued at $90,400. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 6.10% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the stock. BlackRock Fund Advisors increased its position in Supernus Pharmaceuticals by 9.6% in the second quarter. BlackRock Fund Advisors now owns 3,099,268 shares of the specialty pharmaceutical company’s stock valued at $63,132,000 after buying an additional 272,279 shares during the last quarter. Vanguard Group Inc. increased its position in Supernus Pharmaceuticals by 10.0% in the second quarter. Vanguard Group Inc. now owns 1,956,476 shares of the specialty pharmaceutical company’s stock valued at $39,854,000 after buying an additional 177,648 shares during the last quarter. Bank of New York Mellon Corp increased its position in Supernus Pharmaceuticals by 34.3% in the second quarter. Bank of New York Mellon Corp now owns 1,659,604 shares of the specialty pharmaceutical company’s stock valued at $33,806,000 after buying an additional 423,835 shares during the last quarter. Acadian Asset Management increased its position in Supernus Pharmaceuticals by 126.9% in the fourth quarter. Acadian Asset Management now owns 1,632,683 shares of the specialty pharmaceutical company’s stock valued at $21,940,000 after buying an additional 913,129 shares during the last quarter. Finally, Acadian Asset Management LLC increased its position in Supernus Pharmaceuticals by 4.7% in the second quarter. Acadian Asset Management LLC now owns 1,527,277 shares of the specialty pharmaceutical company’s stock valued at $31,110,000 after buying an additional 67,870 shares during the last quarter. Institutional investors and hedge funds own 94.66% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.